Over the last 12 months, two Immix Biopharma, Inc. executives and directors bought shares on the open market, about $10,000 in total, and none of them sold.
Morris Gabriel S (CFO) made the biggest buy, worth around $5,067. C-suite participation is part of the picture here.
No open-market insider buying or selling in the last full quarter. Insiders bought in 3 of the last 7 full quarters. 109 investment managers listed IMMX in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | Rachman Ilya M | CEO | Buy | 746 | $6.67 | $5K | SEC |
| Dec 10, 2025 | Morris Gabriel S | CFO | Buy | 770 | $6.58 | $5K | SEC |
| Sep 17, 2025 | Rachman Ilya M | CEO | Buy | 2,500 | $2.02 | $5K | SEC |
| Sep 17, 2025 | Morris Gabriel S | CFO | Buy | 2,600 | $1.97 | $5K | SEC |
| Jun 20, 2025 | Rachman Ilya M | CEO | Buy | 2,178 | $2.30 | $5K | SEC |
| Jun 20, 2025 | Morris Gabriel S | CFO | Buy | 2,225 | $2.28 | $5K | SEC |
| Dec 26, 2024 | Hsu Jason | Director | Buy | 40,000 | $2.19 | $88K | SEC |
| Dec 26, 2024 | Hsu Jason | Director | Buy | 7,700 | $2.17 | $17K | SEC |
| Aug 26, 2024 | Hsu Jason | Director | Buy | 15,000 | $2.23 | $33K | SEC |
| Aug 26, 2024 | Hsu Jason | Director | Buy | 8,100 | $2.25 | $18K | SEC |
| Aug 19, 2024 | Ng Carey | Director | Buy | 10,000 | $1.86 | $19K | SEC |
| Jul 31, 2024 | Hsu Jason | Director | Buy | 6,000 | $2.15 | $13K | SEC |
| Jul 31, 2024 | Hsu Jason | Director | Buy | 3,200 | $2.07 | $7K | SEC |
| Jun 10, 2024 | Rachman Ilya M | CEO | Buy | 2,600 | $2.13 | $6K | SEC |
| Jun 10, 2024 | Morris Gabriel S | CFO | Buy | 2,500 | $2.12 | $5K | SEC |
In the last 12 months Immix Biopharma, Inc. insiders made open-market purchases worth about $10,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in IMMX was filed on 2025-12-10.
109 investment managers reported holding IMMX in SEC Form 13F filings for Q2 2026.
No congressional trades in IMMX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).